Genentech and Inotek Pair Up in PARP Inhibition
This article was originally published in Start Up
Executive SummaryFor the first time, oncology drug development is being grounded in the ability to take advantage of a readily identifiable genetic flaw in certain types of tumor cells. Research reveals that tumor cells containing the BRCA1 or BRCA2 gene variants are exquisitely sensitive to attack by inhibitors of poly (ADP-ribose) polymerase, or PARP. Now comes a deal between PARP specialist Inotek Pharmaceuticals and Genentech.
You may also be interested in...
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.